Early detection and prevention of lung cancer

European Respiratory Review

Volumn 12, Issue 84, 2002, Pages 122-130

  Nackaerts, K ^a   Brambilla, E ^c   Van Zandwijk, N ^e   Bromen, K ^f   Diederich, S ^g   Hirsch, F R ⁱ   Huber, R M ^h   Ninane, V ^b   Leo, F ^j   Thiberville, L ^d   Axelson, O ^k   Demedts, M ^k   Nemery, B ^k   Petit, M R ^k   Spiro, S ^k   Sasco, A J ^k   Van Meerbeeck, J ^k  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d ROUEN UNIVERSITY HOSPITAL   (France)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g UNIVERSITY OF MÜNSTER   (Germany)

^h UNIVERSITY OF MUNICH   (Germany)

ⁱ UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^j EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^k NONE

more..

Author keywords

Biological marker; Chemoprevention; Fluorescence bronchoscopy; Retinoids; Second primary tumour; Spiral computed tomography scan

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; BETA CAROTENE; ISOTRETINOIN; RETINOID; RETINOL; RETINOL PALMITATE; TUMOR MARKER;

BRONCHOSCOPY; BRONCHUS MUCOSA; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER SCREENING; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONFERENCE PAPER; DIET SUPPLEMENTATION; DRUG EFFECT; EARLY DIAGNOSIS; HUMAN; LUNG CANCER; MOLECULAR BIOLOGY; PRECANCER; PRIMARY PREVENTION; SECOND CANCER; SMOKING CESSATION; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SPUTUM ANALYSIS; THORAX RADIOGRAPHY;

EID: 0038486120     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (86)

1. Shields PG, Harris CC. Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J Clin Oncol 2000; 18: 2309-2315.
2. Fong KM, Sekido Y, Minna JD. Molecular pathogenesis of lung cancer. J Thorac Cardiovasc Surg 1999; 118: 1136-1152.
3. Hirsch FR, Franklin WA, Gazdar AF, Bunn PA Jr. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res 2001; 7: 5-22.
4. Gazdar A, Lam S, Wistuba II. Molecular and cytologic techniques of early detection. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, Minna JD, eds. Lung Cancer: Principles and Practice. Philadelphia, Lippincott Williams and Wilkins, 2000; pp. 407-424.
5. Fontana RS, Sanderson DR, Taylor WF, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic Study. Am Rev Respir Dis 1984; 130: 561-565.
6. Frost JK, Ball WC, Levin ML, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins Study. Am Rev Respir Dis 1984; 130: 549-554.
7. Flehinger BJ, Melamed MR, Zaman MB, Heelan RT, Perchick WP, Martini N. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Memorial Sloan-Kettering Study. Am Rev Respir Dis 1984; 130: 555-560.
8. Kubik A, Parkin DM, Khlat M, Erkan J, Polak J, Adamec M. Lack of benefit from semi-annual screening for cancer of the lung: follow-up report of a randomized controlled trial of population of high-risk males in Czechoslovakia. Int J Cancer 1990; 45: 26-33.
9. Porter JC, Spiro SG. Detection of early lung cancer. Thorax 2000; 55: Suppl. 1, S56-S62.
10. Strauss GM, Gleason RE, Sugarbaker DJ. Chest X-ray screening improves outcome in lung cancer. A reappraisal of randomized trials on lung cancer screening. Chest 1995; 107: 270S-279S.
11. Strauss GM, Gleason RE, Sugarbaker DJ. Screening for lung cancer. Another look; a different view. Chest 1997; 111: 754-768.
12. Kaneko M, Eguchi K, Ohmatsu H, et al. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology 1996; 201: 798-802.
13. Sone S, Takashima S, Li F, et al. Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 1998; 351: 1242-1245.
14. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999; 354: 99-105.
15. Midthun DE, Swensen SJ, Jett JR, et al. Screening for lung cancer with low-dose spiral computed tomography. Lung Cancer 2000; 29: Suppl. 1, 241.
16. Diederich S, Wormanns D, Lenzen H, et al. Screening for early lung cancer with low-dose computed tomography of the chest. Results of baseline examinations in 919 asymptomatic smokers. Eur Radiol 2000; 10: S253.
17. Henschke CI, Naidich DP, Yankelevitz DF, et al. Early Lung Cancer Action Project. Initial findings on repeat screening. Cancer 2001; 92: 153-159.
18. International Commission on Radiological Protection. 1990 Recommendations. Publication 60. Oxford, Pergamon Press, 1991.
19. Patz EF, Goodman PC, Bepler G. Screening for lung cancer. N Engl J Med 2000; 343: 1627-1633.
20. Kramer BS. Lung cancer screening. In: Perry MC, ed. American Society of Clinical Oncology. Educational Book. Philadelphia, WB Saunders Co., 2000; pp. 50-53.
21. Karp DD, Mulshine JL, Henschke CI. Non-small cell lung cancer: screening, new imaging and prevention. In: Perry MC, ed. American Society of Clinical Oncology. Educational Book. Philadelphia, WB Saunders Co., 2000; pp. 487-502.
22. Tockman MS, Gupta PK, Myers JD, et al. Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: a new approach to early lung cancer detection. J Clin Oncol 1988; 6: 1685-1693.
23. Mulshine JL. Reducing lung cancer risk. Early detection. Chest 1999; 116: 493S-496S.
24. Qiao Y-L, Tockman MS, Li L, et al. A case-cohort study of an early biomarker of lung cancer in a screening cohort of Yunnan tin miners in China. Cancer Epidemiol Biomarkers Prev 1997; 6: 893-900.
25. Tockman MS, Mulshine JL, Piantadosi S, et al. Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/ B1 overexpression. Clin Cancer Res 1997; 3: 2237-2246.
26. Mulshine JL, Henschke CI. Prospects for lung cancer screening. Lancet 2000; 355: 592-593.
27. Payne PW, Sebo TJ, Doudkine A, et al. Sputum screening by quantitative microscopy: a reexamination of a portion of the National Cancer Institute Cooperative Early Lung Cancer Study. Mayo Clin Proc 1997; 72: 697-704.
28. Lam S, Palcic B, Garner D, et al. Lung cancer control strategy in the new millennium. Lung Cancer 2000; 29: Suppl. 2, 145.
29. Gazdar AF, Minna JD. Molecular detection of early lung cancer. J Natl Cancer Inst 1999; 91: 299-301.
30. Mao L, Hruban RH, Boyle JO, et al. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 1994; 54: 1634-1637.
31. Ahrendt SA, Chow JT, Xu L-H, et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 1999; 91: 332-339.
32. Miozzo M, Sozzi G, Musso K, et al. Microsatellite alterations in bronchial and sputum specimens of lung cancer patients. Cancer Res 1996; 56: 2285-2288.
33. Kersting M, Friedl C, Kraus A, Behn M, Pankow W, Schuermann M. Differential frequencies of p16INK4a promotor hypermethylation, p53 mutation and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol 2000; 18: 3221-3229.
34. Virmani AK, Rathi A, Zöchbauer-Müller S, et al. Promoter methylation and silencing of the retinoic acid receptorgene in lung carcinomas. J Natl Cancer Inst 2000; 92: 1303-1307.
35. Zöchbauer-Müller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001; 61: 249-255.
36. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000; 60: 5954-5958.
37. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998; 95: 11891-11896.
38. Rom WN, Hay JG, Lee TC, Jiang Y, Tchou-Wong KM. Molecular and genetic aspects of lung cancer. Am J Respir Crit Care Med 2000; 161: 1355-1367.
39. Saccomanno G, Archer VE, Auerbach O, Saunders RP, Brennan LM. Development of carcinoma of the lung as reflected in exfoliated cells. Cancer 1974; 33: 256-270.
40. Band P, Feldstein M, Saccomanno G. Reversibility of bronchial marked atypia: implication for chemoprevention. Cancer Detect Prev 1986; 9: 157-160.
41. Risse EKJ, Vooijs GP, van't Hof MA. Diagnostic significance of 'severe dysplasia' in sputum cytology. Acta Cytol 1988; 32: 629-634.
42. Venmans BJW, van Boxem TJM, Smit EF, Postmus PE, Sutedja TG. Outcome of bronchial carcinoma in situ. Chest 2000; 117: 1572-1576.
43. Lam S, MacAulay C. Endoscopic detection of preneoplastic lesions. In: Brambilla C, Brambilla E, eds. Lung Tumors. Fundamental Biology and Clinical Management. Grenoble, Marcel Dekker, 1999; pp. 473-480.
44. Hirsch FR, Pridiville SA, Miller YE, et al. Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study. J Natl Cancer Inst 2001; 43: 1385-1391.
45. Lam S, Kennedy T, Unger M, et al. Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest 1998; 113: 696-702.
46. Mitsudomi T, Lam S, Shirakusa T, Gazdar AF. Detection and sequencing of p53 gene mutations in bronchial biopsy samples in patients with lung cancer. Chest 1993; 104: 362-365.
47. Thiberville L, Payne P, Vielkind J, et al. Evidence of cumulative gene losses with progression of premalignant epithelial lesions to carcinoma of the bronchus. Cancer Res 1995; 55: 5133-5139.
48. Gazdar AF, Lam S, Wistuba II. Molecular and cytologic techniques of early detection. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, Minna JD, eds. Lung Cancer: Principles and Practice. Philadelphia, Lippincott Williams and Wilkins, 2000; pp. 407-424.
49. Wistuba II, Behrens C, Milchgrub S, et al. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 1999; 18: 643-650.
50. Becker HD, Herth F, Mueller K. Endobronchial ultrasound for detection of early cancer. Lung Cancer 2000; 29: Suppl. 1, 244.
51. Fujimoto JG. Optical coherence tomography for the diagnosis of neoplasia. Lung Cancer 2000; 29: Suppl. 2, 89.
52. Britton J. Buproprion: a new treatment for smokers. BMJ 2000; 321: 65-66.
53. Britton J, Jarvis M, McNeill A, Bates C, Cuthbertson L, Godfrey C. Treating nicotine addiction. Not a medical problem? Am J Respir Crit Care Med 2001; 164: 13-15.
54. Samet JM. The epidemiology of lung cancer. Chest 1993; 103: 20S-29S.
55. Jemal A, Chu KC, Tarone RE. Recent trends in lung cancer mortality in the United States. J Natl Cancer Inst 2001; 93: 277-283.
56. Mao L, Lee JS, Kurie JM, et al. Clonal genetic alterations in the lung of current and former smokers. J Natl Cancer Inst 1997; 89: 857-862.
57. Wistuba II, Lam S, Behrens C, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 1997; 89: 1366-1373.
58. Wistuba II, Behrens C, Virmani AK, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 2000; 60: 1949-1960.
59. Park IW, Wistuba II, Maitra A, et al. Multiple clonal abnormalities in the bronchial epithelium of patients with lung cancer. J Natl Cancer Inst 1999; 91: 1863-1868.
60. Slaughter DP, Southwick HW, Smejkal W. 'Field cancerization' in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953; 6: 963-968.
61. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogues (retinoids). Fed Proc 1976; 35: 1332-1338.
62. Hong WK. Molecular targets for chemoprevention. In: Perry MC, ed. American Society of Clinical Oncology. Educational Book. Philadelphia, WB Saunders Co., 1998; pp. 4-7.
63. Bollag W, Hartmann HR. Prevention and therapy of cancer with retinoids in animals and man. Cancer Surv 1983; 2: 293-314.
64. Lippman SM, Benner SE, Hong WK. Cancer chemoprevention. J Clin Oncol 1994; 12: 851-873.
65. Lee JS, Lippman SM, Benner SE, et al. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 1994; 12: 937-945.
66. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-1035.
67. Omenn GS, Goodman GE, Thornquist MD, et al. Risk factors for lung cancer and for intervention effects in CARET, the beta-carotene and retinol efficacy trial. J Natl Cancer Inst 1996; 88: 1550-1559.
68. Omenn GS, Goodman GE, Thornquist M, et al. Effects of combination of beta-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150-1155.
69. Wang X-D, Liu C, Bronson RT, Smith DE, Krinsky N, Russell M. Retinoid signaling and activator protein-1 expression in ferrets given beta-carotene supplements and exposed to tobacco smoke. J Natl Cancer Inst 1999; 91: 60-66.
70. Hennekens CH, Buring JE, Manson JE, et al. Lack of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334: 1145-1149.
71. Lee I-M, Cook NR, Manson JE, Buring JE, Hennekens CH. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst 1999; 91: 2102-2106.
72. Ratnasinghe D, Forman MR, Tangrea JA, et al. Serum carotenoids are associated with increased lung cancer risk among alcohol drinkers, but not among non-drinkers in a cohort of tin miners. Alcohol Alcoholism 2000; 35: 355-360.
73. Hong WK, Lippman JM, Itri L, et al. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 1990; 323: 795-801.
74. Pastorino U, Infante I, Maioli M, et al. Adjuvant treatment of stage I lung cancer with high dose vitamin A. J Clin Oncol 1993; 11: 1216-1222.
75. van Zandwijk N, Dalesio O, Pastorino U, et al. EURO-SCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. J Natl Cancer Inst 2000; 92: 977-986.
76. Lippmann SM, Lee JJ, Karp DD, et al. Randomized phase III Intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small cell lung cancer. J Natl Cancer Inst 2001; 93: 605-618.
77. van Zandwijk N, Pastorino U, De Vries N, et al. Smoking analysis of Euroscan, the chemoprevention study of the EORTC Head & Neck and Lung Cancer Cooperative groups in patients with cancer of the upper and lower airways. Lung Cancer 2000; 29: Suppl. 1, 219.
78. Mathe G, Gouveia J, Hercend TM, et al. Correlation between precancerous bronchial metaplasia and cigarette consumption, and preliminary results of retinoid treatment. Cancer Detect Prev 1982; 5: 461-466.
79. Martinet Y, Hirsch FR, Martinet N, Vignaud JM, Mulshine JL. Clinical and biological basis of lung cancer prevention. Early lung cancer detection. Basel, Birkhäuser Verlag, 1998.
80. Brambilla E, Gazzeri S, Lantuejoul S, et al. p53 mutant immunophenotype and deregulation of p53 transcription pathway (bcl2, bax, waf1) in precursor bronchial lesions of lung cancer. Clin Cancer Res 1998; 4: 1609-1618.
81. Brambilla E, Gazzeri S, Moro D, Lantuejoul S, Veyrenc S, Brambilla C. Alterations of Rb pathway (Rb-p16INK4-cyclin D1) in preinvasive bronchial lesions. Clin Cancer Res 1999; 5: 243-250.
82. Lee JS, Lippman SM, Hong WK, et al. Determination of biomarkers for intermediate endpoints in chemoprevention trials. Cancer Res 1992; 52: Suppl. 9, 2707s-2710s.
83. Soria JC, Moon C, Wang L, et al. Effects of N-(4-Hydroxyphenyl) retinamide on hTERT expression in the bronchial epithelium of cigarette smokers. J Natl Cancer Inst 2001; 93: 1257-1263.
84. Sun SY, Yue P, Kelloff GJ, et al. Identification of retinamides that are more potent than N-(4-Hydroxyphenyl) retinamide in inhibiting growth and apoptosis of human head and neck and lung cancer cells. Cancer Epidemiol Biomarkers Prev 2001; 10: 595-601.
85. Omenn GS. Chemoprevention of lung cancer is proving difficult and frustrating, requiring new approaches. J Natl Cancer Inst 2000; 92: 959-960.
86. Hong WK. Lung cancer chemoprevention in the 21st century: genetics, risk modeling, and molecular targets. Lung Cancer 2000; 29: Suppl. 2, 41.